Mark Rubin
Prof. Mark Rubin is a leader in the fields of prostate cancer biology and precision medicine as it applies to all cancers. Rubin’s laboratory led a series of landmark studies defining distinct molecular features of prostate cancer, revealing pathways that are perturbed and drive different types of this cancer. Prof. Rubin has translated many of his genomic discoveries into clinical tests that are currently patented and standardly used in the diagnosis and treatment of prostate cancer. In May 2017, Prof. Rubin joined the University of Bern as Professor and Director of the Department for Biomedical Research and also as Project Leader for Precision Medicine at the University Hospital of Bern.